Polydex Pharmaceuticals (POLXF) Inactive 10-Q2007 Q3 Quarterly report

Filed: 14 Dec 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: aggregate, American, award, disclosed, dryer, fluctuate, Frost, indirect, mentioned, Microbicidal, pending, repatriation, Senior, small, spray, Submission, Sullivan, Technologie, Unregistered

Removed: absence, achieve, adversely, afford, alter, altogether, approve, assert, assurance, attention, biotechnology, breadth, brought, candidate, cease, challenged, circumvented, claim, collaboration, commence, commercialization, commercialize, commercializing, commercially, comparable, complex, considerable, contested, costly, covering, defend, delay, depend, dependent, develop, developed, developing, developmental, discontinued, discovery, diversion, eligible, encounter, enter, equivalent, explore, factual, failure, favor, FDA, found, governmental, impose, incur, independently, ineffective, infringe, infringement, infringing, inherent, initiate, innovative, instituted, intercompany, interference, internationally, invalidated, inventorship, liable, licensed, licensing, limit, literature, local, manner, meaningfully, merit, obtain, performing, position, preclinical, preclude, prevent, profitability, proprietary, protect, protection, publication, question, recently, reduced, regulated, reimbursement, rely, resolved, rigorously, scientific, secrecy, secret, set, shown, side, Specifically, strategy, subject, substantial, successful, successfully, suffer, superior, suspension, sustained, technical, technology, Trademark, unable, undesirable, uneconomical, unintended, unknown, unpatented, unsafe, valid, withdrawn

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

POLXF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In condition with the Quarterly Report on Form 10-Q of Polydex Pharmaceuticals Limited (the “Company”) for the fiscal quarter ended October 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, George G. Usher, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

By: /s/ George G. Usher

George G. Usher,

Chief Executive Officer

December 14, 2006

A signed original of this written statement required by section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.